93503-50-5

Basic information

• Product Name: 3-Cyclohexene-1-carboxylic acid, 4-(2-phenyl-1H-indol-3-yl)-
• CAS NO: 93503-50-5
• Molecular Formula: C21H19NO2
• Molecular Weight: 317.387
• Mol File: 93503-50-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-Cyclohexene-1-carboxylic acid, 4-(2-phenyl-1H-indol-3-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Cyclohexene-1-carboxylic acid, 4-(2-phenyl-1H-indol-3-yl)-(93503-50-5)
• EPA Substance Registry System: 3-Cyclohexene-1-carboxylic acid, 4-(2-phenyl-1H-indol-3-yl)-(93503-50-5)

Safety Data

• Hazardous Substances Data: 93503-50-5(Hazardous Substances Data)

Upstream product

• 948-65-2 2-phenyl-indole 
• 874-61-3 4-oxocyclohexanecarboxylic acid 

Downstream Products

• 93503-51-6 methyl 4-(2-phenyl-1H-indol-3-yl)-3-cyclohexene-1-carboxylate 
• 93503-61-8 4-(2-Phenyl-1-propyl-1H-indol-3-yl)-3-cyclohexene-1-carboxylic acid 
• 93503-67-4 cis-4-(1-methyl-2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acid methyl ester 
• 93503-69-6 trans-4-(1-methyl-2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acid methyl ester 
• 93503-66-3 cis-4-(1-methyl-2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acid 
• 93503-68-5 trans-4-(1-methyl-2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acid 
• 93503-57-2 methyl 4-(1-methyl-2-phenyl-1H-indol-3-yl)-3-cyclohexene-1-carboxylate 
• 93503-56-1 4-(1-methyl-2-phenyl-1H-indol-3-yl)-3-cyclohexene-1-carboxylic acid 
• 97227-64-0 methyl 4-(1-methyl-2-phenyl-1H-indol-3-yl)benzoate 
• 93503-74-3 4-(2-phenyl-1H-indol-3-yl)benzoic acid methyl ester 
• 93503-75-4 4-(1-methyl-2-phenyl-1H-indol-3-yl)-benzoic acid 
• 93503-73-2 4-(2-phenyl-1H-indol-3-yl)benzoic acid 
• 93503-59-4 4-(1-ethyl-2-phenyl-1H-indol-3-yl)-3-cyclohexene-1-carboxylic acid 

Relevant articles and documents

Syntheses and complement inhibitory activities of 4-(2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acids

The syntheses of 4-(2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acids are described. These compounds express potent in vitro inhibition of the human classical complement pathway, and qualitative SAR have been determined. Several of the in vitro active